KMT2A and acute myeloid leukemia: On average, MLLr/MLL-PTD AML cell lines tested were more sensitive to fadraciclib than AML cell lines without MLLr/MLL-PTD (IC50/70/90 values; p = 0.048, 0.035 and 0.03, respectively; see inset Fig 4A).